Description: Quanterix is a company digitizing biomarker analysis with the goal of advancing the science of precision health. The company’s digital health solution, Simoa, has the potential to change the way in which healthcare is provided today by giving researchers the ability to closely examine the continuum from health to disease. Quanterix’ technology is designed to enable much earlier disease detection, better prognoses and enhanced treatment methods to improve the quality of life and longevity of the population for generations to come. The technology is currently being used for research applications in several therapeutic areas, including oncology, neurology, cardiology, inflammation and infectious disease. The company was established in 2007 and is located in Lexington, Massachusetts.
Home Page: www.quanterix.com
QTRX Technical Analysis
Building 1
Billerica,
MA
01821
United States
Phone:
617 301 9400
Officers
| Name | Title |
|---|---|
| Dr. Masoud Toloue Ph.D. | Pres, CEO & Director |
| Dr. David R. Walt Ph.D. | Co-Founder, Chairman of Scientific Advisory Board & Independent Director |
| Mr. Michael A. Doyle | CFO & Treasurer |
| Mr. Bruce J. Bal | VP of Operations, Service & Quality |
| Mr. Daniel Pikora | Chief Operating Officer |
| Dr. David C. Duffy Ph.D. | Sr. VP of R&D and CTO |
| David Panzerella | VP of Sales |
| Dr. Mark T. Roskey Ph.D. | Sr. VP of Strategic Partnerships |
| Ms. Mary Ellen Cortizas | VP of Laboratory Services & CRO |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Life Sciences Tools & Services |
| GIC Sub-Industry: | Life Sciences Tools & Services |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.2923 |
| Price-to-Sales TTM: | 4.4708 |
| IPO Date: | 2017-12-07 |
| Fiscal Year End: | December |
| Full Time Employees: | 460 |